Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF. 

Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu

-Sam Fazeli, Bloomberg Intelligence, Director of Research: Healthcare, Defence, Industrials & Auto, discusses the latest in the biotech sector. Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine.
Separately, Merck & Co. won US regulatory approval of a pill called Lipfendra to reduce LDL cholesterol.

-Matt Henriksson, Bloomberg Intelligence Senior Equity Analyst, discusses earnings from Abbott Laboratories. Abbott Laboratories raised its 2026 profit guidance after a stronger-than-expected second quarter driven by improved performance across most of its business lines. The company now expects adjusted earnings to fall between $5.45 to $5.60 a share this year, and shares rose 14% after the announcement.

-Mandeep Singh, Global Head of Tech Research for Bloomberg Intelligence, discusses Taiwan Semiconductor Manufacturing Co. raising its spending and revenue projections for the year, reflecting confidence that growth in demand for chips and data centers will extend into 2027 and beyond. Separately, Uber Technologies Inc. has agreed to buy Delivery Hero SE in a deal that values the German food-delivery company at $14.8 billion and expands the US firm’s global operations.

See omnystudio.com/listener for privacy information.